PMID- 34638225
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211016
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 19
DP  - 2021 Sep 22
TI  - Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment 
      for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study 
      (OTILIA) in 824 Patients.
LID - 10.3390/cancers13194739 [doi]
LID - 4739
AB  - In the single-arm non-interventional OTILIA study, patients with newly diagnosed 
      International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-IV 
      ovarian cancer received bevacizumab (15 mg/kg every 3 weeks for up to 15 months) 
      and standard carboplatin-paclitaxel. The primary aim was to assess safety and 
      progression-free survival (PFS). Subgroup analyses according to age were 
      prespecified. The analysis population included 824 patients (453 aged <70 years, 
      371 aged >/=70 years). At data cutoff, the median bevacizumab duration was 13.8 
      months. Grade >/=3 adverse events (AEs), serious AEs, and AEs leading to 
      bevacizumab discontinuation were more common in older than younger patients, 
      whereas treatment-related AEs were less common. Median PFS was 19.4 months, with 
      no clear difference according to age (20.0 vs. 19.3 months in patients <70 vs. 
      >/=70 years, respectively). One-year OS rates were 92% and 90%, respectively. Mean 
      change from baseline in global health status/quality of life showed a clinically 
      meaningful increase over time. In German routine oncology practice, PFS and 
      safety were similar to reported randomized phase 3 bevacizumab trials in more 
      selected populations. There was no notable reduction in effectiveness and 
      tolerability in patients aged >/=70 years; age alone should not preclude use of 
      bevacizumab-containing therapy. ClinicalTrials.gov: NCT01697488.
FAU - Sehouli, Jalid
AU  - Sehouli J
AD  - Department of Gynecology with Center for Oncological Surgery, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, 
      Charite-Universitatsmedizin Berlin, 13353 Berlin, Germany.
FAU - Mustea, Alexander
AU  - Mustea A
AD  - Department of Gynecology, Greifswald Medical University, 17489 Greifswald, 
      Germany.
FAU - Oskay-Ozcelik, Guelten
AU  - Oskay-Ozcelik G
AUID- ORCID: 0000-0001-7302-1409
AD  - Praxisklinik Krebsheilkunde fur Frauen, 13597 Berlin, Germany.
FAU - Keller, Maren
AU  - Keller M
AD  - Nord-Ostdeutsche Gesellschaft fur Gynakologische Onkologie (NOGGO) e.V., 
      Schwedenstrasse 9, 13359 Berlin, Germany.
FAU - Richter, Rolf
AU  - Richter R
AUID- ORCID: 0000-0003-2965-8730
AD  - Department of Gynecology with Center for Oncological Surgery, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, 
      Charite-Universitatsmedizin Berlin, 13353 Berlin, Germany.
FAU - Tome, Oliver
AU  - Tome O
AD  - St Vincentius-Kliniken, 76135 Karlsruhe, Germany.
FAU - Woopen, Hannah
AU  - Woopen H
AD  - Department of Gynecology with Center for Oncological Surgery, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, 
      Charite-Universitatsmedizin Berlin, 13353 Berlin, Germany.
FAU - Sommer-Joos, Ann-Katrin
AU  - Sommer-Joos AK
AD  - Roche Pharma AG, D-79639 Grenzach-Wyhlen, Germany.
FAU - Grabowski, Jacek P
AU  - Grabowski JP
AD  - Department of Gynecology with Center for Oncological Surgery, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, 
      Charite-Universitatsmedizin Berlin, 13353 Berlin, Germany.
FAU - Armbrust, Robert
AU  - Armbrust R
AD  - Department of Gynecology with Center for Oncological Surgery, Corporate Member of 
      Freie Universitat Berlin and Humboldt-Universitat zu Berlin, 
      Charite-Universitatsmedizin Berlin, 13353 Berlin, Germany.
FAU - Wimberger, Pauline
AU  - Wimberger P
AUID- ORCID: 0000-0002-7380-577X
AD  - Department of Gynecology, Carl Gustav Carus University Dresden, Technische 
      Universitat Dresden, 01307 Dresden, Germany.
LA  - eng
SI  - ClinicalTrials.gov/NCT01697488
GR  - n/a/Roche Pharma AG/
PT  - Journal Article
DEP - 20210922
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8507543
OTO - NOTNLM
OT  - anti-angiogenic
OT  - bevacizumab
OT  - chemotherapy
OT  - ovarian cancer
OT  - platinum-taxane
COIS- Jalid Sehouli reports honoraria from AstraZeneca, Clovis Oncology, Eisai, Johnson 
      & Johnson, MSD Oncology, Olympus Medical Systems, Pfizer, PharmaMar, Tesaro, 
      Teva; consulting/advisory roles for AstraZeneca, Clovis Oncology, Lilly, Merck, 
      MSD Oncology, Pfizer, PharmaMar, Tesaro; research funding from AstraZeneca, 
      Bayer, Clovis Oncology, Merck, MSD Oncology, Pfizer, PharmaMar, Tesaro-all to 
      institution; and travel/accommodation/expenses from AstraZeneca, Clovis Oncology, 
      MSD Oncology, PharmaMar, Roche Pharma AG, Tesaro. Alexander Mustea reports 
      consulting/advisory roles for AstraZeneca, Roche. Guelten Oskay-Ozcelik reports 
      honoraria from Roche, Novartis, AstraZeneca, Amgen, Riemser, MSD; and 
      consulting/advisory role for Roche, Novartis, AstraZeneca, MSD. Hannah Woopen 
      reports travel/accommodation/expenses from Medac. Ann-Katrin Sommer-Joos is an 
      employee of Roche Pharma AG and holds a share in Roche. Jacek P. Grabowski 
      reports honoraria from AstraZeneca, Clovis Oncology, Pfizer, Riemser, Roche, 
      Tesaro; consulting/advisory role for AstraZeneca, Clovis Oncology, Pfizer, 
      Riemser, Roche, Tesaro; research funding from AstraZeneca, MSD, Riemser, 
      Tesaro-all to institution; and travel/accommodation/expenses from Molecular 
      Health, Tesaro. Pauline Wimberger reports honoraria from Roche, AstraZeneca, 
      Clovis Oncology, Eisai, Novartis, Amgen, MSD, Merck Oncology, Pfizer, PharmaMar, 
      Tesaro, Teva; research funding from Amgen, Novartis, Roche; and 
      consulting/advisory roles for Roche, MSD, Tesaro, Novartis, Amgen, Clovis, 
      Pfizer, AstraZeneca, Eisai. Maren Keller, Rolf Richter, Oliver Tome, and Robert 
      Armbrust report no conflict of interest.
EDAT- 2021/10/14 06:00
MHDA- 2021/10/14 06:01
PMCR- 2021/09/22
CRDT- 2021/10/13 01:01
PHST- 2021/08/18 00:00 [received]
PHST- 2021/09/15 00:00 [revised]
PHST- 2021/09/16 00:00 [accepted]
PHST- 2021/10/13 01:01 [entrez]
PHST- 2021/10/14 06:00 [pubmed]
PHST- 2021/10/14 06:01 [medline]
PHST- 2021/09/22 00:00 [pmc-release]
AID - cancers13194739 [pii]
AID - cancers-13-04739 [pii]
AID - 10.3390/cancers13194739 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Sep 22;13(19):4739. doi: 10.3390/cancers13194739.